Parallel Biosystems Analysis: $4M Raised
What is Parallel Biosystems?
Parallel Biosystems develops immunotherapies using immune organoids and AI to create effective drugs, aiming to revolutionize drug discovery without traditional clinical trials.
Product Features & Capabilities
- Trial-in-a-Dish, Disease Modeling, Target Discovery, Predict drug safety in diverse populations, Create realistic disease models, Identify novel drug targets
How much Parallel Biosystems raised
Seed - $4.3 million
December 20, 2022Lead Investor: Refactor Capital, Breakout Ventures, Jeff Dean (SVP of Google AI), Y Combinator, several biotech-focused funds, and senior executives at global pharmaceutical co
Who are the founders of Parallel Biosystems
RD
Robert DiFazio
Co-Founder and CEO
Investors
- Refactor Capital
- Breakout Ventures
- Y Combinator
- Jeff Dean (SVP of Google AI)
- Gaingels
Market Focus
Parallel Biosystems primarily focuses on the biotechnology industry, specifically in the development of immunotherapies using immune organoids and artificial intelligence to create safe and effective therapies without traditional clinical trials.
Business Model
Biotech partnerships and seed funding drive revenue through drug discovery innovations.
Competitors Overview
The main competitors of Parallel Biosystems in the immunotherapy development market include:
- Chimeron Bio: This company focuses on developing immuno-oncology treatments that aim to disrupt the tumor immune microenvironment. They enhance the patient's immune system to recognize and destroy ca
See something that needs updating? Suggest edits to this profile.